iHuman Q1 Adj EPADS $0.06 Down From $0.15 YoY, Sales $32.55M Down From $38.62M YoY
Portfolio Pulse from Benzinga Newsdesk
iHuman reported a significant decline in its Q1 adjusted EPADS, dropping to $0.06 from $0.15 year-over-year. Sales also decreased to $32.55 million from $38.62 million in the same period last year.
June 28, 2024 | 7:34 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
iHuman's Q1 adjusted EPADS fell to $0.06 from $0.15 YoY, and sales decreased to $32.55M from $38.62M, indicating a significant decline in financial performance.
The significant year-over-year decline in both adjusted EPADS and sales suggests a weakening financial performance, which is likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100